Bausch Health Q4 Revenue Rises 9%, Cash Flow Drops $205M After Red Sea Trial Failure
Bausch Health's Red Sea trials missed primary endpoints, prompting a pipeline review, while Q4 adjusted operating cash flow fell $205M due to cash interest timing shifts. Revenue rose 9% reported (5% organic) with Salix and Salta growing 11% and 18%, and net debt cut by $1.7B via debt exchange.
1. Q4 Financial Results
The company reported a 9% revenue increase on a reported basis and 5% on an organic basis, excluding Bausch & Lomb. Salix and Salta segments delivered top-line growth of 11% and 18% respectively. Adjusted operating cash flow for the fourth quarter declined by $205 million year over year due to shifts in cash interest payment timing.
2. Pipeline and Business Strategy
Red Sea trials failed to meet primary endpoints, triggering a review of new development opportunities. Management emphasized continued focus on repaying debt, reinvesting in existing products, accelerating pipeline projects and evaluating monetization options for Bausch & Lomb to enhance shareholder value.
3. Debt Restructuring and Capital Structure
The company reduced net debt by several hundred million dollars and improved its debt maturity profile by approximately $1.7 billion through a strategic debt exchange, strengthening liquidity and refinancing flexibility.